As hormone-based obesity treatments gain prominence, GLP-1 receptor agonists have established themselves as frontrunners in this rapidly advancing field (Müller et al., 2019). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.